Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 ...

DelveInsight’s B7-H3 Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging B7-H3 inhibitors, market share of individual therapies, and ...

B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H3-CARs ...

B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...

B7-H3 (CD276) is an immune checkpoint molecule aberrantly overexpressed on a wide range of tumour cells and associated stromal elements, while showing limited distribution in normal tissues. Its dual ...

Detailed price information for Radiopharm Theranostics Limited ADR (RADX-Q) from The Globe and Mail including charting and trades.

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel ...

Data to be presented across two posters at the 2026 American Society of Clinical (ASCO) Annual MeetingCombined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metast ...

Targeting CHK1 pathway to induce cytotoxic response to histone deactylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and ...